News

Nature15y
Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis | Leukemia - Nature
Patients, treatment regimens and samples. Between 12 September 2003 and 11 July 2007, MRD flow and ASO IGH RQ-PCR were applied in parallel to 530 peripheral blood or bone marrow samples from 69 ...
Oncology Nurse Advisor5y
MRD Status Assessed by Flow Cytometry Predicts Treatment Efficacy in Newly Diagnosed Multiple Myeloma
MRD Status Assessed by Flow Cytometry Predicts Treatment Efficacy in Newly Diagnosed Multiple Myeloma Susan Moench, PhD, PA-C Publish Date January 15, 2020 ...
Scientific Research Publishing14y
A comparison of flow cytometry detection of minimal residual disease and chimerism kinetics in chronic lymphocytic leukemia patients after allogeneic hematopoietic stem cell ...
Determination of minimal residual disease (MRD) remains crucial for the follow-up after therapy in chronic lymphocytic leukemia (CLL) patients. Chimerism was assessed by short tandem repeat (STR)-PCR ...
Labroots8d
Comprehensive Analysis using Next Generation Flow™ in Multiple Myeloma MRD
The upcoming webinar will delve into the advanced applications of Next Generation Flow™ in the analysis of Minimal Residual Disease (MRD) in Multiple Myeloma (MM). Dr. Juan Flores-Montero, a ...
IEEE1y
On automated Flow Cytometric analysis for MRD estimation of Acute Lymphoblastic Leukaemia: A comparison among different approaches - IEEE Xplore
Minimal Residual Disease (MRD) is a powerful risk-stratification marker in the treatment of primary and relapsed childhood Acute Lymphoblastic Leukemia. Flow Cytometry is a fast and sensitive method ...